


PRODUCT INFORMATION



Fevipirant

Item No. 20263

CAS Registry No.: 872365-14-5
Formal Name: 2-methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1 H -pyrrolo[2,3b]pyridine-3-acetic acid
Synonyms: NVP-QAW039, QAW039
MF: C₁₉H₁₇F₃N₂O₄S
FW: 426.4
Purity: ≥98%
UV/Vis.: λ_{max}: 224, 291 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fevipirant is supplied as a crystalline solid. A stock solution may be made by dissolving the fevipirant in the solvent of choice, which should be purged with an inert gas. Fevipirant is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of fevipirant in ethanol is approximately 1 mg/ml and approximately 10 mg/ml in DMSO and DMF.

Fevipirant is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, fevipirant should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Fevipirant has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Fevipirant is a DP₂/CRTH₂ antagonist (K_i = 1.05 nM).¹ It reduces shape change of eosinophils induced by prostaglandin D₂ (PGD₂; Item No. 12010) with IC₅₀ values of 0.4 and 0.44 nM for isolated human eosinophils and human whole blood, respectively. Fevipirant inhibits PGD₂-induced release of IL-5 and IL-13 in isolated human CD4⁺ Th2 cells (IC₅₀s = 2.56 and 1.4 nM, respectively). It reduces the number of eosinophils in bronchoalveolar lavage fluid (BALF) in a mouse model of asthma (ED₅₀ = ~1 mg/kg).²

References

1. Sykes, D. A., Bradley, M. E., Riddy, D. M., *et al.* Fevipirant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy. *Mol. Pharmacol.* **89**(5), 593-605 (2016).
2. Sandham, D., Asano, K., Barker, L., *et al.* Fevipirant, a potent selective prostaglandin D₂ receptor 2 (DP₂) antagonist, dose-dependently inhibits pulmonary inflammation in a mouse model of asthma. *Am. J. Respir. Crit. Care Med.* **197**, A1418 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/11/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM